1 Dopamine 2 and somatostatin 1 – 5 receptors coexpression in clinically non - functioning pituitary adenomas
نویسندگان
چکیده
Filip Gabalec, Monika Drastikova, David Netuka, Vaclav Masopust, Tomas Cesak, Josef Machac, Josef Marek, Jan Cap, Martin Beranek. 4 Department of Internal Medicine – Hematology, Institute of Clinical Biochemistry and Diagnostics, and Department of Neurosurgery, University Hospital Hradec Kralove and Charles University in Prague, Faculty of Medicine in Hradec Kralove; Department of Neurosurgery, 1 Faculty of Medicine, Charles University in Prague and Central Military Hospital Prague; Dept. of Neurosurgery, University Hospital, Olomouc; 3 Department of Medicine, 1st Faculty of Medicine, Charles University in Prague; Czech Republic.
منابع مشابه
Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.
This study investigated quantitated expression of dopamine 2 receptor (D2R) and somatostatin receptors of the five types (SSTR1-SSTR5) in a large series of clinically non-functioning pituitary adenomas (CNFAs). Co-expression of these receptors in individual adenomas was studied as well as correlation between receptor types. Adenoma tissue from 198 patients who underwent surgery for CNFAs was an...
متن کاملCombined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
Pituitary tumours express both somatostatin and dopamine receptors. Medical treatment with somatostatin analogues is a cornerstone of GH- and TSH-secreting tumours, while treatment with dopamine agonists is a cornerstone of prolactin-secreting tumours. Dopamine agonists have also demonstrated some efficacy in patients with GH- and TSH-secreting adenomas. Neither ACTH-secreting nor clinically no...
متن کاملDifferential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Somatostatin analogs and dopamine agonists are clinically used for medical therapy of functioning pituitary tumors, such as growth hormone- and prolactin-secreting tumors, however, their effects on ACTH-secreting tumors are controversial. This study was aimed to determine whether somatostatin receptor (SSTR) subtype (1-5) and dopamine receptor type 2 (D2R) are differentially expressed in pituit...
متن کاملThe clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.
The role of somatostatin and dopamine receptors as molecular targets for the treatment of patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin receptor agonists are considered milestones for the medical therapy of these tumours. However, in recent years, the knowledge of the expression of subtypes of somatostatin and dopamine receptors in pituitary adenomas, a...
متن کاملMedical therapy for clinically non-functioning pituitary adenomas.
Surgery is the first-line treatment of patients with clinically non-functioning pituitary adenomas (NFAs). Because of lack of clinical syndrome these tumours are diagnosed with a variable delay, when patients suffer from compression symptoms (hypopituitarism, headache and visual field defects) due to the extension of the tumour outside the pituitary fossa. Surgery is followed by residual tumour...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014